KR20210080418A - 신규한 용도 - Google Patents

신규한 용도 Download PDF

Info

Publication number
KR20210080418A
KR20210080418A KR1020217013853A KR20217013853A KR20210080418A KR 20210080418 A KR20210080418 A KR 20210080418A KR 1020217013853 A KR1020217013853 A KR 1020217013853A KR 20217013853 A KR20217013853 A KR 20217013853A KR 20210080418 A KR20210080418 A KR 20210080418A
Authority
KR
South Korea
Prior art keywords
alkyl
substituted
pde1 inhibitor
independently
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217013853A
Other languages
English (en)
Korean (ko)
Inventor
로버트 이. 데이비스
킴벌리 이. 바노버
Original Assignee
인트라-셀룰라 써래피스, 인코퍼레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인트라-셀룰라 써래피스, 인코퍼레이티드. filed Critical 인트라-셀룰라 써래피스, 인코퍼레이티드.
Publication of KR20210080418A publication Critical patent/KR20210080418A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217013853A 2018-10-21 2019-10-21 신규한 용도 Ceased KR20210080418A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862748517P 2018-10-21 2018-10-21
US62/748,517 2018-10-21
PCT/US2019/057260 WO2020086481A1 (en) 2018-10-21 2019-10-21 Novel uses

Publications (1)

Publication Number Publication Date
KR20210080418A true KR20210080418A (ko) 2021-06-30

Family

ID=70331921

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217013853A Ceased KR20210080418A (ko) 2018-10-21 2019-10-21 신규한 용도

Country Status (11)

Country Link
US (2) US12194042B2 (enExample)
EP (1) EP3866808A4 (enExample)
JP (1) JP7480135B2 (enExample)
KR (1) KR20210080418A (enExample)
CN (1) CN113194955A (enExample)
AU (1) AU2019364274C1 (enExample)
BR (1) BR112021007571A2 (enExample)
CA (1) CA3117148A1 (enExample)
IL (1) IL282396A (enExample)
MX (1) MX2021004531A (enExample)
WO (1) WO2020086481A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220184240A1 (en) * 2019-04-12 2022-06-16 Intra-Cellular Therapies, Inc. Organic compounds
US12410175B2 (en) 2019-09-03 2025-09-09 Intra-Cellular Therapies, Inc. Compounds
EP4284806A4 (en) * 2021-01-27 2025-02-26 Intra-Cellular Therapies, Inc. Salt crystals

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1585771A (zh) * 2001-11-09 2005-02-23 先灵公司 多环鸟嘌呤衍生物磷酸二酯酶v抑制剂
PT2152712E (pt) 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
EP2939676A1 (en) * 2007-12-06 2015-11-04 Intra-Cellular Therapies, Inc. Organic compounds
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
TW201206937A (en) * 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
CA2961212C (en) 2014-09-17 2024-02-06 Intra-Cellular Therapies, Inc. Compounds and methods
EP4112053B1 (en) 2016-10-11 2024-02-14 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Treatment of synucleinopathies

Also Published As

Publication number Publication date
CN113194955A (zh) 2021-07-30
JP2022505471A (ja) 2022-01-14
AU2019364274B2 (en) 2024-10-17
US20250090536A1 (en) 2025-03-20
BR112021007571A2 (pt) 2021-07-27
US20210379072A1 (en) 2021-12-09
WO2020086481A1 (en) 2020-04-30
MX2021004531A (es) 2021-09-10
US12194042B2 (en) 2025-01-14
IL282396A (en) 2021-06-30
EP3866808A4 (en) 2023-04-12
JP7480135B2 (ja) 2024-05-09
AU2019364274C1 (en) 2025-04-10
EP3866808A1 (en) 2021-08-25
AU2019364274A1 (en) 2021-06-03
CA3117148A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
US20250090536A1 (en) Uses
EP2081431B1 (en) Organic compounds
JP6696904B2 (ja) 製剤および医薬組成物
KR20080097443A (ko) 덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물
JP2016006042A (ja) 有機化合物
JP2020023496A6 (ja) 有機化合物
JP7749896B2 (ja) 気分障害のための新規ガンマアミノ酪酸型受容体モジュレーター
JP2002544232A (ja) Ｎ−デスメチルゾピクロンの製造方法および使用方法
US20140271890A1 (en) Controlled-release pharmaceutical composition
JP5491475B2 (ja) ムスカリン性受容体ｍ１拮抗剤を使用する精神状態の処置
AU2015317527A1 (en) Compounds and methods
RU2836384C2 (ru) Новые применения
HK40057178A (en) Novel uses
CN101472571A (zh) 使用毒蕈碱型受体m1拮抗剂治疗心理学病况
RU2477634C2 (ru) Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов
JP2025160326A (ja) 処置方法
KR20090031908A (ko) Ｓｌｖ308 및 ｌ-ｄｏｐａ를 포함하는 병용 제제

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R17-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000